Michigan Medicine
Annual Hematologic Malignancies Symposium
Saturday, October 10, 2026
9:00 am – 3:30 pm
Check in and continental breakfast at 8:30 am
Embedded Files
The Amway Grand Plaza
Grand Rapids, MI
The Speakers
The Speakers
Keynote Speakers
Keynote Speakers
Jonathan Licht, MD
President and Chief Scientific Officer
Van Andel Institute, Grand Rapids, Michigan
Jolanta Grembecka, PhD
Professor, Michigan Medicine, Pathology
Michigan Medicine
Division of Hematology Oncology
Michigan Medicine
Division of Hematology Oncology
Erica Campagnaro, MD
Erica Campagnaro, MD
Michigan Medicine
Division of Hematology Oncology
Michael Deininger, MD, PhD
Michael Deininger, MD, PhD
Michigan Medicine
Division of Hematology Oncology
Michigan Medicine
Division of Hematology Oncology
Kamran Mirza, MBBS, PhD
Kamran Mirza, MBBS, PhD
Michigan Medicine, Pathology
Carlos Murga-Zamalioa, MD
Carlos Murga-Zamalioa, MD
University of Chicago-Illinois, Pathology
Michigan Medicine
Division of Hematology Oncology
Michigan Medicine
Division of Hematology Oncology
Target Audience
This symposium is intended for physicians, physicians in training (residents/fellows), medical students, pharmacists, and advanced practice providers in the field of malignant hematology.
Description with expected results
The University of Michigan Rogel Cancer Center (UMRCC) is an NCI-designated comprehensive cancer center with a history of excellence in cancer care, education, and research. The UMRCC catchment area includes the entire State of Michigan, its ≈10M residents, and ≈750 community medical oncologists. After completing this activity participants will be able to utilize current, state of the art updates in the diagnosis, risk stratification, and treatment of all hematologic malignancies. They will also be able to enroll patients to the ground breaking and often lifesaving clinical trials. After completion of this activity, patient outcomes will be improved by having been enrolled in the appropriate clinical trials designed specifically to treat Hematologic Malignancies.
Faculty Planner
Ryan Wilcox, MD, PhD
Department of Internal Medicine,
Division of Hematology/Oncology
Section Head, Lymphoma & Myeloma
Target Audience
This symposium is intended for physicians, physicians in training (residents/fellows), medical students, pharmacists, and advanced practice providers in the field of malignant hematology.
Description with expected results
The University of Michigan Rogel Cancer Center (UMRCC) is an NCI-designated comprehensive cancer center with a history of excellence in cancer care, education, and research. The UMRCC catchment area includes the entire State of Michigan, its ≈10M residents, and ≈750 community medical oncologists. After completing this activity participants will be able to utilize current, state of the art updates in the diagnosis, risk stratification, and treatment of all hematologic malignancies. They will also be able to enroll patients to the ground breaking and often lifesaving clinical trials. After completion of this activity, patient outcomes will be improved by having been enrolled in the appropriate clinical trials designed specifically to treat Hematologic Malignancies.
Faculty Planner
Ryan Wilcox, MD, PhD
Department of Internal Medicine,
Division of Hematology/Oncology
Section Head, Lymphoma & Myeloma
Financial Disclosure Information
Individuals in control of content have no relevant financial relationships with companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Accreditation and Credit Designation
Accreditation and Credit Designation
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Michigan Medical School designates this live activity for a maximum of - 5.0 AMA PRA Category 1 Credit(s).™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Michigan Medical School designates this live activity for a maximum of - 5.0 AMA PRA Category 1 Credit(s).™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Please note: Attendance must be registered within 6 months to be awarded credit. To complete an evaluation for this session please login to MiCME and go to the Claim Credits and View Certificates on the Credit Center card. Locate the activity under Awarded Credits and complete the evaluation. There will also be a QR code will be available on site at the symposium.
Please note: Attendance must be registered within 6 months to be awarded credit. To complete an evaluation for this session please login to MiCME and go to the Claim Credits and View Certificates on the Credit Center card. Locate the activity under Awarded Credits and complete the evaluation. There will also be a QR code will be available on site at the symposium.
Page updated
Report abuse